Esperion Therapeutics (ESPR) Operating Leases (2019 - 2026)

Esperion Therapeutics has reported Operating Leases for 8 years, with the latest figure at $861000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 56.34% year-over-year to $861000.0; the trailing twelve-month figure through Mar 2026 stood at $861000.0 (down 56.34% YoY), and the FY2025 full-year result was $653000.0, down 87.7% from the prior year.
• Operating Leases for Q1 2026 stood at $861000.0, up from $653000.0 in the prior quarter.
• The five-year high for Operating Leases was $5.3 million in Q4 2024, with the low at $47000.0 in Q3 2022.
• Historically, Operating Leases has averaged $1.8 million across 5 years, with a median of $1.3 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 96.42% — and 2023, when it jumped 4259.57%.
• Esperion Therapeutics' Operating Leases stood at $665000.0 in 2022, then surged by 354.14% to $3.0 million in 2023, then jumped by 75.86% to $5.3 million in 2024, then sank by 87.7% to $653000.0 in 2025, then jumped by 31.85% to $861000.0 in 2026.
• The last three Operating Leases figures came in at $861000.0 (Q1 2026), $653000.0 (Q4 2025), and $767000.0 (Q3 2025), per Business Quant data.